218 related articles for article (PubMed ID: 29439008)
21. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
Wang Y; Lin J; Cui J; Han T; Jiao F; Meng Z; Wang L
Oncotarget; 2017 Feb; 8(6):9354-9365. PubMed ID: 28030840
[TBL] [Abstract][Full Text] [Related]
22. Primary cultures of human myasthenia gravis thymus and normal thymus. Studies of cell morphology, cell proliferative pattern and localization of alpha-bungarotoxin binding sites on cultured thymic cells.
Matsumoto Y; Furuya A; Kobayashi T; Tsukagoshi H
J Neurol Sci; 1986 Sep; 75(2):121-33. PubMed ID: 3760907
[TBL] [Abstract][Full Text] [Related]
23. Increased number of Hassall's corpuscles in myasthenia gravis patients with thymic hyperplasia.
Matsui N; Ohigashi I; Tanaka K; Sakata M; Furukawa T; Nakagawa Y; Kondo K; Kitagawa T; Yamashita S; Nomura Y; Takahama Y; Kaji R
J Neuroimmunol; 2014 Apr; 269(1-2):56-61. PubMed ID: 24556356
[TBL] [Abstract][Full Text] [Related]
24. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
Roberts JA; Gonzalez RS; Das S; Berlin J; Shi C
Hum Pathol; 2017 Dec; 70():49-54. PubMed ID: 29037958
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
26. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of tumour size in completely resected thymic epithelial tumours.
Fukui T; Fukumoto K; Okasaka T; Kawaguchi K; Nakamura S; Hakiri S; Ozeki N; Hirakawa A; Tateyama H; Yokoi K
Eur J Cardiothorac Surg; 2016 Dec; 50(6):1068-1074. PubMed ID: 27999073
[TBL] [Abstract][Full Text] [Related]
28. [Morphologic criteria for the diagnosis of thymic pathology in myasthenia].
Rykov VA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(7):73-8. PubMed ID: 7124229
[No Abstract] [Full Text] [Related]
29. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
30. Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia.
Shiao YM; Lee CC; Hsu YH; Huang SF; Lin CY; Li LH; Fann CS; Tsai CY; Tsai SF; Chiu HC
J Neuroimmunol; 2010 Apr; 221(1-2):101-6. PubMed ID: 20223524
[TBL] [Abstract][Full Text] [Related]
31. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim HK; Shin BK; Kim BH
Oncotarget; 2016 Dec; 7(49):80426-80434. PubMed ID: 27741514
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
33. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
[TBL] [Abstract][Full Text] [Related]
34. [PD1/PD-L1 immunohistochemistry in thoracic oncology: Where are we?].
Hofman P; Ilié M; Lassalle S; Long E; Bence C; Butori C; Hofman V
Ann Pathol; 2017 Feb; 37(1):39-45. PubMed ID: 28159404
[TBL] [Abstract][Full Text] [Related]
35. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.
Chen Y; Zhang Y; Chai X; Gao J; Chen G; Zhang W; Zhang Y
Biomed Res Int; 2018; 2018():5830547. PubMed ID: 29850538
[TBL] [Abstract][Full Text] [Related]
36. Distribution of thymic hormones in thymic tumors and myasthenic thymus.
Wu MH; Low TL
Proc Natl Sci Counc Repub China B; 1996 Jan; 20(1):1-5. PubMed ID: 8765340
[TBL] [Abstract][Full Text] [Related]
37. Difference in the distribution of tumor-infiltrating CD8+ T cells and FOXP3+ T cells between micronodular thymoma with lymphoid stroma and micronodular thymic carcinoma with lymphoid stroma.
Yagi H; Nakaguro M; Ito M; Okumura Y; Takahashi S; Aoshima Y; Enomoto Y; Meguro S; Kawasaki H; Kosugi I; Shimoyama Y; Ogawa H; Tateyama H; Iwashita T
Pathol Int; 2021 Jul; 71(7):453-462. PubMed ID: 33819365
[TBL] [Abstract][Full Text] [Related]
38. Detection of human parvovirus B19 infection in the thymus of patients with thymic hyperplasia-associated myasthenia gravis.
Gong L; Li Y; Li X; Tu Q; Mou X; Wang S; Wan Y; Lu Q; Wang J; Zhang W; Zhu S; Han X; Yao L; Zhang J; Huang G; Zhang W
Clin Microbiol Infect; 2019 Jan; 25(1):109.e7-109.e12. PubMed ID: 29649594
[TBL] [Abstract][Full Text] [Related]
39. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions.
Yagyuu T; Hatakeyama K; Imada M; Kurihara M; Matsusue Y; Yamamoto K; Obayashi C; Kirita T
Oral Oncol; 2017 May; 68():36-43. PubMed ID: 28438290
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
